Current insights into apolipoprotein E and the immune response in Alzheimer's disease.

Alzheimer's disease apolipoprotein E immune responses

Journal

Immunological reviews

ISSN: 1600-065X

Titre abrégé: Immunol Rev

Pays: England

ID NLM: 7702118

Informations de publication

Date de publication:
24 Oct 2024

Historique:

medline: 24 10 2024

pubmed: 24 10 2024

entrez: 24 10 2024

Statut: aheadofprint

Résumé

Alzheimer's disease (AD) is a progressive neurological disorder and the most common cause of dementia. Genetic analyses identified apolipoprotein E (APOE) as the strongest genetic risk for late-onset AD. Studies have shown that ApoE modulates AD pathogenesis in part by influencing amyloid-β (Aβ) deposition. However, ApoE also appears to regulate elements of AD via regulation of innate immune response, especially through microglial and astrocyte activation. In model systems, it also regulates changes in T-cells. This review focuses on the key findings that have advanced our understanding of the role of ApoE in the pathogenesis of AD and the current view of innate immune response regulated by ApoE in AD, while discussing open questions and areas for future research.

Identifiants

DOI: 10.1111/imr.13414 PMID: 39445515

pubmed: 39445515

doi: 10.1111/imr.13414

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Subventions

Organisme : Cure Alzheimer's Fund

Organisme : Tau Consortium

Organisme : JPB Foundation

Organisme : NIA NIH HHS

ID : 1U19AG069701

Pays : United States

Organisme : NINDS NIH HHS

ID : RF1NS090934

Pays : United States

Informations de copyright

Références

Long JM, Holtzman DM. Alzheimer disease: an update on pathobiology and treatment strategies. Cell. 2019;179(2):312‐339.

Hardy J, Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics. Science. 2002;297(5580):353‐356.

Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. N Engl J Med. 2012;367(9):795‐804.

Jack CR Jr, Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119‐128.

Pimenova AA, Raj T, Goate AM. Untangling genetic risk for Alzheimer's disease. Biol Psychiatry. 2018;83(4):300‐310.

Shore VG, Shore B. Heterogeneity of human plasma very low density lipoproteins. Separation of species differing in protein components. Biochemistry. 1973;12(3):502‐507.

Utermann G. Isolation and partial characterization of an arginine‐rich apolipoprotein from human plasma very‐low‐density lipoproteins: apolipoprotein E. Hoppe Seylers Z Physiol Chem. 1975;356(7):1113‐1121.

Holtzman DM, Morris JC, Goate AM. Alzheimer's disease: the challenge of the second century. Sci Transl Med. 2011;3(77):77sr71.

Vance JM, Farrer LA, Huang Y, et al. Report of the APOE4 National Institute on Aging/Alzheimer disease sequencing project consortium working group: reducing APOE4 in carriers is a therapeutic goal for Alzheimer's disease. Ann Neurol. 2024;95(4):625‐634.

Corder EH, Saunders AM, Strittmatter WJ, et al. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science. 1993;261(5123):921‐923.

Dickson DW, Heckman MG, Murray ME, et al. APOE epsilon4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology. 2018;91(12):e1182‐e1195.

Geroldi C, Pihlajamaki M, Laakso MP, et al. APOE‐epsilon4 is associated with less frontal and more medial temporal lobe atrophy in AD. Neurology. 1999;53(8):1825‐1832.

Koriath C, Lashley T, Taylor W, et al. ApoE4 lowers age at onset in patients with frontotemporal dementia and tauopathy independent of amyloid‐beta copathology. Alzheimers Dement (Amst). 2019;11:277‐280.

Sawa A, Amano N, Yamada N, et al. Apolipoprotein E in progressive supranuclear palsy in Japan. Mol Psychiatry. 1997;2(4):341‐342.

Wang H, Chang TS, Dombroski BA, et al. Whole‐genome sequencing analysis reveals new susceptibility loci and structural variants associated with progressive supranuclear palsy. Mol Neurodegener. 2024;19(1):61.

Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science. 1988;240(4852):622‐630.

Boyles JK, Pitas RE, Wilson E, Mahley RW, Taylor JM. Apolipoprotein E associated with astrocytic glia of the central nervous system and with nonmyelinating glia of the peripheral nervous system. J Clin Invest. 1985;76(4):1501‐1513.

Pitas RE, Boyles JK, Lee SH, Foss D, Mahley RW. Astrocytes synthesize apolipoprotein E and metabolize apolipoprotein E‐containing lipoproteins. Biochim Biophys Acta. 1987;917(1):148‐161.

Blue ML, Williams DL, Zucker S, Khan SA, Blum CB. Apolipoprotein E synthesis in human kidney, adrenal gland, and liver. Proc Natl Acad Sci USA. 1983;80(1):283‐287.

Newman TC, Dawson PA, Rudel LL, Williams DL. Quantitation of apolipoprotein E mRNA in the liver and peripheral tissues of nonhuman primates. J Biol Chem. 1985;260(4):2452‐2457.

Wehler R. Attitudes toward mental illness and dependency among hospitalized psychiatric patients. Psychol Rep. 1979;44(1):283‐286.

Williams DL, Dawson PA, Newman TC, Rudel LL. Apolipoprotein E synthesis in peripheral tissues of nonhuman primates. J Biol Chem. 1985;260(4):2444‐2451.

Fagan AM, Holtzman DM, Munson G, et al. Unique lipoproteins secreted by primary astrocytes from wild type, apoE (−/−), and human apoE transgenic mice. J Biol Chem. 1999;274(42):30001‐30007.

Garai K, Verghese PB, Baban B, Holtzman DM, Frieden C. The binding of apolipoprotein E to oligomers and fibrils of amyloid‐beta alters the kinetics of amyloid aggregation. Biochemistry. 2014;53(40):6323‐6331.

Strittmatter WJ, Weisgraber KH, Huang DY, et al. Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform‐specific effects and implications for late‐onset Alzheimer disease. Proc Natl Acad Sci USA. 1993;90(17):8098‐8102.

Grimm MOW, Michaelson DM, Hartmann T. Omega‐3 fatty acids, lipids, and apoE lipidation in Alzheimer's disease: a rationale for multi‐nutrient dementia prevention. J Lipid Res. 2017;58(11):2083‐2101.

Baker HN, Gotto AM Jr, Jackson RL. The primary structure of human plasma high density apolipoprotein glutamine I (ApoA‐I). II. The amino acid sequence and alignment of cyanogen bromide fragments IV, III, and I. J Biol Chem. 1975;250(7):2725‐2738.

Huebbe P, Rimbach G. Evolution of human apolipoprotein E (APOE) isoforms: gene structure, protein function and interaction with dietary factors. Ageing Res Rev. 2017;37:146‐161.

Li WH, Tanimura M, Luo CC, Datta S, Chan L. The apolipoprotein multigene family: biosynthesis, structure, structure‐function relationships, and evolution. J Lipid Res. 1988;29(3):245‐271.

Weisgraber KH. Apolipoprotein E: structure‐function relationships. Adv Protein Chem. 1994;45:249‐302.

Dong LM, Wilson C, Wardell MR, et al. Human apolipoprotein E. role of arginine 61 in mediating the lipoprotein preferences of the E3 and E4 isoforms. J Biol Chem. 1994;269(35):22358‐22365.

Wilson C, Mau T, Weisgraber KH, Wardell MR, Mahley RW, Agard DA. Salt bridge relay triggers defective LDL receptor binding by a mutant apolipoprotein. Structure. 1994;2(8):713‐718.

Bradley WA, Gilliam EB, Gotto AM Jr, Gianturco SH. Apolipoprotein‐E degradation in human very low density lipoproteins by plasma protease(s): chemical and biological consequences. Biochem Biophys Res Commun. 1982;109(4):1360‐1367.

Innerarity TL, Friedlander EJ, Rall SC Jr, Weisgraber KH, Mahley RW. The receptor‐binding domain of human apolipoprotein E. Binding of apolipoprotein E fragments. J Biol Chem. 1983;258(20):12341‐12347.

Weisgraber KH. Apolipoprotein E distribution among human plasma lipoproteins: role of the cysteine‐arginine interchange at residue 112. J Lipid Res. 1990;31(8):1503‐1511.

Weisgraber KH, Innerarity TL, Mahley RW. Abnormal lipoprotein receptor‐binding activity of the human E apoprotein due to cysteine‐arginine interchange at a single site. J Biol Chem. 1982;257(5):2518‐2521.

Shaw RA, Buchko GW, Wang G, et al. Infrared spectroscopy of human apolipoprotein fragments in SDS/D2O: relative lipid‐binding affinities and a novel amide I assignment. Biochemistry. 1997;36(47):14531‐14538.

Wang G, Treleaven WD, Cushley RJ. Conformation of human serum apolipoprotein A‐I(166‐185) in the presence of sodium dodecyl sulfate or dodecylphosphocholine by 1H‐NMR and CD. Evidence for specific peptide‐SDS interactions. Biochim Biophys Acta. 1996;1301(3):174‐184.

Chen Y, Strickland MR, Soranno A, Holtzman DM. Apolipoprotein E: structural insights and links to Alzheimer disease pathogenesis. Neuron. 2021;109(2):205‐221.

DeMattos RB, Rudel LL, Williams DL. Biochemical analysis of cell‐derived apoE3 particles active in stimulating neurite outgrowth. J Lipid Res. 2001;42(6):976‐987.

Hatters DM, Voss JC, Budamagunta MS, Newhouse YN, Weisgraber KH. Insight on the molecular envelope of lipid‐bound apolipoprotein E from electron paramagnetic resonance spectroscopy. J Mol Biol. 2009;386(1):261‐271.

Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E: structure determines function, from atherosclerosis to Alzheimer's disease to AIDS. J Lipid Res. 2009;50(Suppl):S183‐S188.

Peters‐Libeu CA, Newhouse Y, Hatters DM, Weisgraber KH. Model of biologically active apolipoprotein E bound to dipalmitoylphosphatidylcholine. J Biol Chem. 2006;281(2):1073‐1079.

Raussens V, Fisher CA, Goormaghtigh E, Ryan RO, Ruysschaert JM. The low density lipoprotein receptor active conformation of apolipoprotein E. Helix organization in n‐terminal domain‐phospholipid disc particles. J Biol Chem. 1998;273(40):25825‐25830.

Strickland MR, Rau MJ, Summers B, et al. Apolipoprotein E secreted by astrocytes forms antiparallel dimers in discoidal lipoproteins. Neuron. 2024;112(7):1100‐1109 e1105.

Zorich N, Jonas A, Pownall HJ. Activation of lecithin cholesterol acyltransferase by human apolipoprotein E in discoidal complexes with lipids. J Biol Chem. 1985;260(15):8831‐8837.

Castellano JM, Kim J, Stewart FR, et al. Human apoE isoforms differentially regulate brain amyloid‐beta peptide clearance. Sci Transl Med. 2011;3(89):89ra57.

Fagan AM, Watson M, Parsadanian M, Bales KR, Paul SM, Holtzman DM. Human and murine ApoE markedly alters a beta metabolism before and after plaque formation in a mouse model of Alzheimer's disease. Neurobiol Dis. 2002;9(3):305‐318.

Holtzman DM, Bales KR, Tenkova T, et al. Apolipoprotein E isoform‐dependent amyloid deposition and neuritic degeneration in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA. 2000;97(6):2892‐2897.

Morris JC, Roe CM, Xiong C, et al. APOE predicts amyloid‐beta but not tau Alzheimer pathology in cognitively normal aging. Ann Neurol. 2010;67(1):122‐131.

Reiman EM, Chen K, Liu X, et al. Fibrillar amyloid‐beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease. Proc Natl Acad Sci USA. 2009;106(16):6820‐6825.

Bien‐Ly N, Gillespie AK, Walker D, Yoon SY, Huang Y. Reducing human apolipoprotein E levels attenuates age‐dependent Abeta accumulation in mutant human amyloid precursor protein transgenic mice. J Neurosci. 2012;32(14):4803‐4811.

Kim J, Jiang H, Park S, et al. Haploinsufficiency of human APOE reduces amyloid deposition in a mouse model of amyloid‐beta amyloidosis. J Neurosci. 2011;31(49):18007‐18012.

Bales KR, Verina T, Dodel RC, et al. Lack of apolipoprotein E dramatically reduces amyloid beta‐peptide deposition. Nat Genet. 1997;17(3):263‐264.

Ulrich JD, Ulland TK, Mahan TE, et al. ApoE facilitates the microglial response to amyloid plaque pathology. J Exp Med. 2018;215(4):1047‐1058.

Liu CC, Zhao N, Fu Y, et al. ApoE4 accelerates early seeding of amyloid pathology. Neuron. 2017;96(5):1024‐1032 e1023.

Huynh TV, Liao F, Francis CM, et al. Age‐dependent effects of apoE reduction using antisense oligonucleotides in a model of beta‐amyloidosis. Neuron. 2017;96(5):1013‐1023 e1014.

Zheng JY, Sun J, Ji CM, et al. Selective deletion of apolipoprotein E in astrocytes ameliorates the spatial learning and memory deficits in Alzheimer's disease (APP/PS1) mice by inhibiting TGF‐beta/Smad2/STAT3 signaling. Neurobiol Aging. 2017;54:112‐132.

Mahan TE, Wang C, Bao X, Choudhury A, Ulrich JD, Holtzman DM. Selective reduction of astrocyte apoE3 and apoE4 strongly reduces Abeta accumulation and plaque‐related pathology in a mouse model of amyloidosis. Mol Neurodegener. 2022;17(1):13.

Yin Z, Rosenzweig N, Kleemann KL, et al. APOE4 impairs the microglial response in Alzheimer's disease by inducing TGFbeta‐mediated checkpoints. Nat Immunol. 2023;24(11):1839‐1853.

Liu CC, Wang N, Chen Y, et al. Cell‐autonomous effects of APOE4 in restricting microglial response in brain homeostasis and Alzheimer's disease. Nat Immunol. 2023;24(11):1854‐1866.

Arriagada PV, Growdon JH, Hedley‐Whyte ET, Hyman BT. Neurofibrillary tangles but not senile plaques parallel duration and severity of Alzheimer's disease. Neurology. 1992;42(3 Pt 1):631‐639.

Josephs KA, Whitwell JL, Ahmed Z, et al. Beta‐amyloid burden is not associated with rates of brain atrophy. Ann Neurol. 2008;63(2):204‐212.

Shi Y, Yamada K, Liddelow SA, et al. ApoE4 markedly exacerbates tau‐mediated neurodegeneration in a mouse model of tauopathy. Nature. 2017;549(7673):523‐527.

Shi Y, Manis M, Long J, et al. Microglia drive APOE‐dependent neurodegeneration in a tauopathy mouse model. J Exp Med. 2019;216(11):2546‐2561.

Wang C, Xiong M, Gratuze M, et al. Selective removal of astrocytic APOE4 strongly protects against tau‐mediated neurodegeneration and decreases synaptic phagocytosis by microglia. Neuron. 2021;109(10):1657‐1674 e1657.

Koutsodendris N, Blumenfeld J, Agrawal A, et al. Neuronal APOE4 removal protects against tau‐mediated gliosis, neurodegeneration and myelin deficits. Nat Aging. 2023;3(3):275‐296.

Litvinchuk A, Huynh TV, Shi Y, et al. Apolipoprotein E4 reduction with antisense oligonucleotides decreases neurodegeneration in a tauopathy model. Ann Neurol. 2021;89(5):952‐966.

Gratuze M, Jiang H, Wang C, Xiong M, Bao X, Holtzman DM. APOE antibody inhibits Abeta‐associated tau seeding and spreading in a mouse model. Ann Neurol. 2022;91(6):847‐852.

Liao F, Li A, Xiong M, et al. Targeting of nonlipidated, aggregated apoE with antibodies inhibits amyloid accumulation. J Clin Invest. 2018;128(5):2144‐2155.

Agarwal A, Gupta V, Brahmbhatt P, et al. Amyloid‐related imaging abnormalities in Alzheimer disease treated with anti‐amyloid‐beta therapy. Radiographics. 2023;43(9):e230009.

Jeremic D, Navarro‐Lopez JD, Jimenez‐Diaz L. Efficacy and safety of anti‐amyloid‐beta monoclonal antibodies in current Alzheimer's disease phase III clinical trials: a systematic review and interactive web app‐based meta‐analysis. Ageing Res Rev. 2023;90:102012.

Sims JR, Zimmer JA, Evans CD, et al. Donanemab in early symptomatic Alzheimer disease: the TRAILBLAZER‐ALZ 2 randomized clinical trial. JAMA. 2023;330(6):512‐527.

van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in early Alzheimer's disease. N Engl J Med. 2023;388(1):9‐21.

Sperling R, Salloway S, Brooks DJ, et al. Amyloid‐related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol. 2012;11(3):241‐249.

Xiong M, Jiang H, Serrano JR, et al. APOE immunotherapy reduces cerebral amyloid angiopathy and amyloid plaques while improving cerebrovascular function. Sci Transl Med. 2021;13(581):eabd7522.

Holtzman DM, Fagan AM, Mackey B, et al. Apolipoprotein E facilitates neuritic and cerebrovascular plaque formation in an Alzheimer's disease model. Ann Neurol. 2000;47(6):739‐747.

Fryer JD, Simmons K, Parsadanian M, et al. Human apolipoprotein E4 alters the amyloid‐beta 40:42 ratio and promotes the formation of cerebral amyloid angiopathy in an amyloid precursor protein transgenic model. J Neurosci. 2005;25(11):2803‐2810.

Xiong M, Wang C, Gratuze M, et al. Astrocytic APOE4 removal confers cerebrovascular protection despite increased cerebral amyloid angiopathy. Mol Neurodegener. 2023;18(1):17.

Krasemann S, Madore C, Cialic R, et al. The TREM2‐APOE pathway drives the transcriptional phenotype of dysfunctional microglia in neurodegenerative diseases. Immunity. 2017;47(3):566‐581 e569.

Keren‐Shaul H, Spinrad A, Weiner A, et al. A unique microglia type associated with restricting development of Alzheimer's disease. Cell. 2017;169(7):1276‐1290 e1217.

Chen X, Holtzman DM. Emerging roles of innate and adaptive immunity in Alzheimer's disease. Immunity. 2022;55(12):2236‐2254.

Chen X, Firulyova M, Manis M, et al. Microglia‐mediated T cell infiltration drives neurodegeneration in tauopathy. Nature. 2023;615(7953):668‐677.

Ramakrishnan A, Piehl N, Simonton B, et al. Epigenetic dysregulation in Alzheimer's disease peripheral immunity. Neuron. 2024;112(8):1235‐1248 e1235.

Acosta‐Baena N, Sepulveda‐Falla D, Lopera‐Gomez CM, et al. Pre‐dementia clinical stages in presenilin 1 E280A familial early‐onset Alzheimer's disease: a retrospective cohort study. Lancet Neurol. 2011;10(3):213‐220.

Arboleda‐Velasquez JF, Lopera F, O'Hare M, et al. Resistance to autosomal dominant Alzheimer's disease in an APOE3 Christchurch homozygote: a case report. Nat Med. 2019;25(11):1680‐1683.

Sepulveda‐Falla D, Sanchez JS, Almeida MC, et al. Distinct tau neuropathology and cellular profiles of an APOE3 Christchurch homozygote protected against autosomal dominant Alzheimer's dementia. Acta Neuropathol. 2022;144(3):589‐601.

Wardell MR, Brennan SO, Janus ED, Fraser R, Carrell RW. Apolipoprotein E2‐Christchurch (136 Arg—ser). New variant of human apolipoprotein E in a patient with type III hyperlipoproteinemia. J Clin Invest. 1987;80(2):483‐490.

He KY, Khramtsova EA, Cabrera‐Socorro A, et al. Characterization of APOE Christchurch carriers in 455,306 UK biobank participants. Mol Neurodegener. 2023;18(1):92.

Lalazar A, Weisgraber KH, Rall SC Jr, et al. Site‐specific mutagenesis of human apolipoprotein E. Receptor binding activity of variants with single amino acid substitutions. J Biol Chem. 1988;263(8):3542‐3545.

Mah D, Zhu Y, Su G, et al. Apolipoprotein E recognizes Alzheimer's disease associated 3‐O Sulfation of heparan sulfate. Angew Chem Int Ed Engl. 2023;62(23):e202212636.

Chen Y, Song S, Parhizkar S, et al. APOE3ch alters microglial response and suppresses Abeta‐induced tau seeding and spread. Cell. 2024;187(2):428‐445 e420.

Nelson MR, Liu P, Agrawal A, et al. The APOE‐R136S mutation protects against APOE4‐driven tau pathology, neurodegeneration and neuroinflammation. Nat Neurosci. 2023;26(12):2104‐2121.

Marino C, Perez‐Corredor P, O'Hare M, et al. APOE Christchurch‐mimetic therapeutic antibody reduces APOE‐mediated toxicity and tau phosphorylation. Alzheimers Dement. 2024;20(2):819‐836.

Le Guen Y, Belloy ME, Grenier‐Boley B, et al. Association of Rare APOE missense variants V236E and R251G with risk of Alzheimer disease. JAMA Neurol. 2022;79(7):652‐663.

van den Maagdenberg AM, Weng W, de Bruijn IH, et al. Characterization of five new mutants in the carboxyl‐terminal domain of human apolipoprotein E: no cosegregation with severe hyperlipidemia. Am J Hum Genet. 1993;52(5):937‐946.

Liu CC, Murray ME, Li X, et al. APOE3‐Jacksonville (V236E) variant reduces self‐aggregation and risk of dementia. Sci Transl Med. 2021;13(613):eabc9375.

Bu G. APOE targeting strategy in Alzheimer's disease: lessons learned from protective variants. Mol Neurodegener. 2022;17(1):51.

Le Guen Y, Raulin AC, Logue MW, et al. Association of African Ancestry‐Specific APOE missense variant R145C with risk of Alzheimer disease. JAMA. 2023;329(7):551‐560.

Hopkins PN, Brinton EA, Nanjee MN. Hyperlipoproteinemia type 3: the forgotten phenotype. Curr Atheroscler Rep. 2014;16(9):440.

Koopal C, Marais AD, Westerink J, Visseren FL. Autosomal dominant familial dysbetalipoproteinemia: a pathophysiological framework and practical approach to diagnosis and therapy. J Clin Lipidol. 2017;11(1):12‐23 e11.

Stalenhoef AF, Malloy MJ, Kane JP, Havel RJ. Metabolism of apolipoproteins B‐48 and B‐100 of triglyceride‐rich lipoproteins in normal and lipoprotein lipase‐deficient humans. Proc Natl Acad Sci USA. 1984;81(6):1839‐1843.

Stalenhoef AF, Malloy MJ, Kane JP, Havel RJ. Metabolism of apolipoproteins B‐48 and B‐100 of triglyceride‐rich lipoproteins in patients with familial dysbetalipoproteinemia. J Clin Invest. 1986;78(3):722‐728.

Rall SC Jr, Weisgraber KH, Innerarity TL, Mahley RW. Structural basis for receptor binding heterogeneity of apolipoprotein E from type III hyperlipoproteinemic subjects. Proc Natl Acad Sci USA. 1982;79(15):4696‐4700.

Bea AM, Larrea‐Sebal A, Marco‐Benedi V, et al. Contribution of APOE genetic variants to dyslipidemia. Arterioscler Thromb Vasc Biol. 2023;43(6):1066‐1077.

Ji ZS, Fazio S, Mahley RW. Variable heparan sulfate proteoglycan binding of apolipoprotein E variants may modulate the expression of type III hyperlipoproteinemia. J Biol Chem. 1994;269(18):13421‐13428.

Ruiz J, Kouiavskaia D, Migliorini M, et al. The apoE isoform binding properties of the VLDL receptor reveal marked differences from LRP and the LDL receptor. J Lipid Res. 2005;46(8):1721‐1731.

Fan K, Francis L, Aslam MM, et al. Investigation of the independent role of a rare APOE variant (L28P; APOE*4Pittsburgh) in late‐onset Alzheimer disease. Neurobiol Aging. 2023;122:107‐111.

Medway CW, Abdul‐Hay S, Mims T, et al. ApoE variant p.V236E is associated with markedly reduced risk of Alzheimer's disease. Mol Neurodegener. 2014;9:11.

Argyri L, Dafnis I, Theodossiou TA, Gantz D, Stratikos E, Chroni A. Molecular basis for increased risk for late‐onset Alzheimer disease due to the naturally occurring L28P mutation in apolipoprotein E4. J Biol Chem. 2014;289(18):12931‐12945.

Chemparathy A, Guen YL, Chen S, et al. APOE loss‐of‐function variants: compatible with longevity and associated with resistance to Alzheimer's disease pathology. Neuron. 2024;112(7):1110‐1116.

Chemparathy A, Le Guen Y, Chen S, et al. APOE loss‐of‐function variants: compatible with longevity and associated with resistance to Alzheimer's disease pathology. Neuron. 2024;112(7):1110‐1116 e1115.

Tensaouti Y, Stephanz EP, Yu TS, Kernie SG. ApoE regulates the development of adult newborn hippocampal neurons. eNeuro. 2018;5(4):ENEURO.0155.

Meyer K, Feldman HM, Lu T, et al. REST and neural gene network dysregulation in iPSC models of Alzheimer's disease. Cell Rep. 2019;26(5):1112‐1127 e1119.

Jackson RJ, Keiser MS, Meltzer JC, et al. APOE2 gene therapy reduces amyloid deposition and improves markers of neuroinflammation and neurodegeneration in a mouse model of Alzheimer disease. Mol Ther. 2024;32(5):1373‐1386.

Zhao L, Gottesdiener AJ, Parmar M, et al. Intracerebral adeno‐associated virus gene delivery of apolipoprotein E2 markedly reduces brain amyloid pathology in Alzheimer's disease mouse models. Neurobiol Aging. 2016;44:159‐172.